American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results From a Phase Ib Study

Rogers KA

  • Presentation # 2631 – Poster
    December 12, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts

Phase I/II Study of MAK683 in Patients With Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma

Ribrag V

  • Presentation # 1422 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts

Real-World Evaluation of the Treatment Landscape for Chronic Lymphocytic Leukemia

Smith TW

  • Presentation # 1559 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound